Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for GLAXO
Revenue projections for GLAXO

GLAXO's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 1.77500
forwardPE 34.13353
debtToEquity 2.09100
earningsGrowth 0.01900
revenueGrowth -0.03100
grossMargins 0.62864
operatingMargins 0.32482
trailingEps 56.45000
forwardEps 67.77500

GLAXO's current ratio, being 1.775, means the company is well-positioned to meet its short-term debt obligations. This reflects GLAXO's strong liquidity, as its cash reserves and current assets provide more than enough coverage for its immediate liabilities.
GLAXO's low growth in both earnings and revenue indicates potential profit shrinkage. This downward trend could be a sign of weakening financial health, signaling challenges for the company's future profitability.
GLAXO's positive gross and operating margins indicate healthy profitability. These margins reflect the company's ability to generate income efficiently from its operations, signaling strong financial performance and effective cost management.
GLAXO's forward EPS exceeding its trailing EPS means that the company is expected to increase profitability in the current financial year. This reflects improved earnings potential, signaling that GLAXO is likely to outperform its previous year's financial performance.

Price projections:

Price projections for GLAXO
Price projections for GLAXO

GlaxoSmithKline Pharmaceuticals Limited's price currently reflects projections without revealing significant risks or opportunities. This status quo implies that investors may experience minimal fluctuations in the stock, leading to a cautious approach in trading decisions until future indicators emerge.

Recommendation changes over time:

Recommendations trend for GLAXO
Recommendations trend for GLAXO


Analysts have shown a buy bias for GLAXO, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to GLAXO, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.